Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany
April 27, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 27, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal
April 26, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 26, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023 16:05 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Mainz Biomed Provides Full Year 2022 Financial Results
April 10, 2023 03:01 ET
|
Mainz BioMed NV
ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V....
Community Oncology Services Global Market Report 2023: Government Investments in Oncology Bolsters $132.5 Billion Industry
April 07, 2023 04:38 ET
|
Research and Markets
Dublin, April 07, 2023 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Opportunities And Strategies To 2032" report has been added to ResearchAndMarkets.com's offering.The...
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
April 05, 2023 08:00 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
TOUR de TUSH RAISES MONEY FOR YOUNG ONSET COLORECTAL CANCER RESEARCH
April 05, 2023 07:00 ET
|
Colon Cancer Coalition
Minneapolis, April 05, 2023 (GLOBE NEWSWIRE) -- Tour de Tush, the month-long virtual cycling event, returns again this year. Held from May 1-31, 2023, Tour de Tush is hosted by the Colon Cancer...
Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany
April 04, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...
Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas
March 29, 2023 03:01 ET
|
Mainz BioMed NV
Mainz Biomed’s proprietary nucleic acid extraction and PCR process proved to be highly effectiveTwo mRNA biomarkers found to be particularly valuable in detecting disease signals in advanced adenoma...
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
March 21, 2023 03:01 ET
|
Mainz BioMed NV
BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...